Preoperative weekly cisplatin, epirubicin, and paclitaxel (PET) improves prognosis in locally advanced breast cancer patients: An update of the Southern Italy Cooperative Oncology Group (SICOG) randomised trial 9908

Annals of Oncology

Volumn 21, Issue 4, 2009, Pages 707-716

  Frasci, G ^a   D'Aiuto, G ^a   Comella, P ^a   D'Aiuto, M ^a   di Bonito, M ^a   Ruffolo, P ^a   Iodice, G ^a   Petrillo, A ^a   Lastoria, S ^a   Oliviero, P ^a   Capasso, I ^a   Montella, M ^a   Siani, C ^b   Santangelo, M ^c   Vizioli, L ^d   Comella, G ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

^c UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^d UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

Breast cancer; Cisplatin; Dose dense; Locally advanced; Neoadjuvant chemotherapy; Weekly paclitaxel

Indexed keywords

CISPLATIN; CYCLOPHOSPHAMIDE; EPIRUBICIN; FLUOROURACIL; GONADORELIN DERIVATIVE; METHOTREXATE; PACLITAXEL; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TAMOXIFEN; TRASTUZUMAB;

ADJUVANT THERAPY; ADULT; ADVANCED CANCER; AGED; ARTICLE; BREAST CANCER; BREAST SURGERY; CANCER GRADING; CANCER RELAPSE; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE FREE SURVIVAL; DOSAGE SCHEDULE COMPARISON; DRUG EFFECT; FEMALE; HUMAN; HUMAN TISSUE; ITALY; MAJOR CLINICAL STUDY; METASTASIS; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; SURVIVAL RATE; TREATMENT RESPONSE;

EID: 77951942987     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdp356     Document Type: Article

References (41)

1. Chia S, Swain SM, Byrd DR, Mankoff DA. Locally advanced and inflammatory breast cancer. J Clin Oncol 2008; 26: 786-790.
2. Huang EH, Tucker SL, Strom EA et al. Postmastectomy radiation improves localregional control and survival for selected patients with locally advanced breast cancer treated with neoadjuvant chemotherapy and mastectomy. J Clin Oncol 2004; 22: 4691-4699.
3. Low JA, Berman AW, Steinberg SM et al. Long-term follow-up for locally advanced and inflammatory breast cancer patients treated with multimodality therapy. J Clin Oncol 2004; 22: 4067-4074.
4. Panades M, Olivotto IA, Speers CH et al. Evolving treatment strategies for inflammatory breast cancer: a population-based survival analysis. J Clin Oncol 2005; 23: 1941-1950.
5. Cristofanilli M, Gonzalez-Angulo AM, Buzdar AU et al. Paclitaxel improves the prognosis in estrogen receptor negative inflammatory breast cancer: the M.D. Anderson Cancer Center experience. Clin Breast Cancer 2004; 4: 415-419.
6. Mazouni C, Kau SW, Frye D et al. Inclusion of taxanes, particularly weekly paclitaxel, in preoperative chemotherapy improves pathologic complete response rate in estrogen receptor-positive breast cancers. Ann Oncol 2007; 18: 874-880.
7. Green MC, Buzdar AU, Smith T et al. Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 weeks. J Clin Oncol 2005; 23: 5983-5992.
8. Ezzat AA, Ibrahim EM, Ajarim DS et al. Phase II study of neoadjuvant paclitaxel and cisplatin for operable and locally advanced breast cancer: analysis of 126 patients. Br J Cancer 2004; 90: 968-974.
9. Hurley J, Doliny P, Reis I et al. Docetaxel, cisplatin, and trastuzumab as primary systemic therapy for human epidermal growth factor receptor 2-positive locally advanced breast cancer. J Clin Oncol 2006; 24: 1831-1838.
10. Lee YJ, Doliny P, Gomez-Fernandez C et al. Docetaxel and cisplatin as primary chemotherapy for treatment of locally advanced breast cancers. Clin Breast Cancer 2004; 5: 371-376.
11. Villman K, Ohd JF, Lidbrink E et al. A phase II study of epirubicin, cisplatin and capecitabine as neoadjuvant chemotherapy in locally advanced or inflammatory breast cancer. Eur J Cancer 2007; 43: 1163-1170.
12. Sirohi B, Arnedos M, Popat S et al. Platinum-based chemotherapy in triple-negative breast cancer. Ann Oncol 2008; 19: 1847-1852.
13. Leong CO, Vidnovic N, DeYoung MP et al. The p63/p73 network mediates chemosensitivity to cisplatin in a biologically defined subset of primary breast cancers. J Clin Invest 2007; 117(5): 1370-1380.
14. Frasci G, D'Aiuto G, Comella P et al. Weekly cisplatin, epirubicin, and paclitaxel with granulocyte colony-stimulating factor support vs triweekly epirubicin and paclitaxel in locally advanced breast cancer: final analysis of a SICOG phase III study. Br J Cancer 2006; 95: 1005-1012.
15. Frasci G, D'Aiuto G, Comella P et al. A 2-month cisplatin-epirubicin-paclitaxel (PET) weekly combination as primary systemic therapy for large operable breast cancer: a phase II study. Ann Oncol 2005; 16: 1268-1275.
16. Frasci G, D'Aiuto G, Comella P et al. Cisplatin-epirubicin-paclitaxel weekly administration in advanced breast cancer: a phase I study of the Southern Italy Cooperative Oncology Group. Breast Cancer Res Treat 1999; 56: 239-252.
17. Frasci G, D'Aiuto G, Comella P et al. Cisplatin-epirubicin-paclitaxel weekly administration with G-CSF support in advanced breast cancer: a Southern Italy Cooperative Oncology Group phase II study. Breast Cancer Res Treat 2000; 62: 87-97.
18. Frasci G, Comella P, Rinaldo M et al. Preoperative weekly cisplatin-epirubicin-paclitaxel with G-CSF support in triple negative large operable breast cancer. Ann Oncol 2009; 20: 1185-1192.
19. Chevallier B, Roche H, Olivier JP et al. Inflammatory breast cancer. Pilot study of intensive induction chemotherapy (FEC-HD) results in a high histologic response rate. Am J Clin Oncol 1993; 16: 223-228.
20. Carey LA, Metzger R, Dees EC et al. American Joint Committee on Cancer tumor-node-metastasis stage after neoadjuvant chemotherapy and breast cancer outcome. J Natl Cancer Inst 2005; 97: 1137-1142.
21. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective analysis of disease. J Natl Cancer Inst 1959; 22: 719-748.
22. Cox D. Regression models and life tables. J R Stat Soc B 1972; 34: 187-220.
23. Kaplan ES, Meier P. Non parametric estimation for incomplete observations. J Am Stat Assoc 1958; 53: 557-580.
24. McGuire SE, Gonzalez-Angulo AM, Huang EH et al. Postmastectomy radiation improves the outcome of patients with locally advanced breast cancer who achieve a pathologic complete response to neoadjuvant chemotherapy. Int J Radiat Oncol Phys 2007; 68: 1004-1009.
25. Jeruss JS, Mittendorf EA, Tucker SR et al. Combined use of clinical and pathologic staging variables to define outcomes for breast cancer patients treated with neoadjuvant therapy. J Clin Oncol 2008; 26: 246-252.
26. Untch M, Konekny G, Ditsch N et al. Dose-dense sequential epirubicin-paclitaxel as preoperative treatment of breast cancer: results of a randomised AGO study. Proc Am Soc Clin Oncol 2002; 21: 34a (Abstr 133).
27. Gianni L, Baselga J, Eiermann W et al. European Cooperative Trial in Operable Breast Cancer Study Group. Feasibility and tolerability of sequential doxorubicin/ paclitaxel followed by cyclophosphamide, methotrexate, and fluorouracil and its effects on tumor response as preoperative therapy. Clin Cancer Res 2005; 11: 8715-8721.
28. Sparano JA, Wang M, Martino S et al. Weekly paclitaxel in the adjuvant treatment of breast cancer. N Engl J Med 2008; 358: 1663-1671.
29. Rastogi P, Anderson SJ, Bear HD et al. Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27. J Clin Oncol 2008; 26: 778-785.
30. Rakha EA, El-Sayed ME, Lee AHS et al. Prognostic significance of Nottingham histologic grade in invasive breast carcinoma. J Clin Oncol 2008; 26: 3153-3158.
31. Spyratos F, Ferrero-Poüs M, Trassard M et al. Correlation between MIB-1 and other proliferation markers: clinical implications of the MIB-1 cutoff value. Cancer 2002; 94: 2151-2159.
32. Liedtke C, Mazouni C, Hess KR et al. Response to neoadjuvant therapy and long-term survival in patients with triple negative breast cancer. J Clin Oncol 2008; 26: 1275-1281.
33. Fasano J, Muggia F. Breast cancer arising in a BRCA-mutated background: therapeutic implications from an animal model and drug development. Ann Oncol 2009; 20: 609-614.
34. Mehta RS. Dose-dense and/or metronomic schedules of specific chemotherapies consolidate the chemosensitivity of triple-negative breast cancer: a step toward reversing triple-negative paradox. J Clin Oncol 2008; 26: 3286-3288.
35. Bertheau P, Turpin E, Rickman DS et al. Exquisite sensitivity of TP53 mutant and basal breast cancers to a dose-dense epirubicin-cyclophosphamide regimen. PLoS Med 2007; 4(3): e90.
36. Loi S, Haibe-Kains B, Desmedt C et al. Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade. J Clin Oncol 2007; 25: 1239-1246.
37. Andre F, Hatzis C, Anderson K et al. Microtubule-associated protein-tau is a bifunctional predictor of endocrine sensitivity and chemotherapy resistance in estrogen receptor-positive breast cancer. Clin Cancer Res 2007; 13: 2061-2067.
38. Berry DA, Cirrincione C, Henderson IC et al. Estrogen-receptor status and outcome of modern chemotherapy for patients with node-positive breast cancer. JAMA 2006; 295: 1658-1667.
39. Jones RL, Salter J, A'hern R et al. The prognostic significance of Ki67 before and after neoadjuvant chemotherapy in breast cancer. Breast Cancer Res Treat 2009; 116: 53-68.
40. Ellis MJ, Tao Y, Luo J et al. Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics. J Natl Cancer Inst 2008; 100: 1380-1388.
41. Chollet P, Amat S, Belembaogo E et al. Is Nottingham prognostic index useful after induction chemotherapy in operable breast cancer? Br J Cancer 2003; 89: 1185-1189.